Immutep Announced Thursday, First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
Portfolio Pulse from Charles Gross
Immutep Limited has announced the first patient has been enrolled and safely dosed in EFTISARC-NEO, the Phase II trial of eftilagimod alpha, in combination with radiotherapy and the anti-PD-1 therapy KEYTRUDA for patients with soft tissue sarcoma. This is the first chemotherapy-free trial to evaluate eftilagimod alpha in a neoadjuvant setting.
July 28, 2023 | 11:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep's initiation of a Phase II trial for eftilagimod alpha could potentially boost its stock as it indicates progress in the company's research and development efforts.
The initiation of a Phase II trial is a significant milestone in a biotech company's development process. This could potentially attract more investors, leading to an increase in the company's stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Merck's KEYTRUDA is being used in combination with eftilagimod alpha in Immutep's Phase II trial. This could potentially have a positive impact on Merck's stock.
The use of Merck's KEYTRUDA in Immutep's trial could potentially increase the visibility and usage of KEYTRUDA, leading to potential revenue growth for Merck.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50